Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Biogen Inc. (NASDAQ:BIIB)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Biogen Inc. (NASDAQ:BIIB). In a filing disclosed on February 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in Biogen stock on January 30th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Hermès International Société en commandite par actions (OTCMKTS:HESAF) on 2/3/2026.
• Purchased $1,001 – $15,000 in shares of Tencent (OTC:TCTZF) on 2/3/2026.
• Purchased $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 2/3/2026.
• Purchased $1,001 – $15,000 in shares of Mitsubishi Heavy Industries (OTCMKTS:MHVYF) on 2/3/2026.
• Purchased $1,001 – $15,000 in shares of Banco Santander (NYSE:SAN) on 2/3/2026.
• Purchased $1,001 – $15,000 in shares of Leonardo (OTCMKTS:FINMF) on 2/3/2026.
• Purchased $1,001 – $15,000 in shares of Costco Wholesale (NASDAQ:COST) on 1/30/2026.
• Purchased $1,001 – $15,000 in shares of Transdigm Group (NYSE:TDG) on 1/30/2026.
• Purchased $1,001 – $15,000 in shares of Cloudflare (NYSE:NET) on 1/30/2026.
• Purchased $1,001 – $15,000 in shares of AutoZone (NYSE:AZO) on 1/30/2026.

Biogen Stock Down 0.0%

Shares of BIIB traded down $0.05 during mid-day trading on Friday, hitting $192.03. 799,205 shares of the company’s stock were exchanged, compared to its average volume of 1,443,122. The stock has a market cap of $28.18 billion, a price-to-earnings ratio of 21.80, a P/E/G ratio of 1.52 and a beta of 0.16. The firm has a fifty day moving average of $180.02 and a two-hundred day moving average of $161.10. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. Biogen Inc. has a twelve month low of $110.04 and a twelve month high of $202.41.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The firm had revenue of $2.28 billion during the quarter, compared to analysts’ expectations of $2.21 billion. During the same period in the prior year, the company posted $3.44 earnings per share. Biogen’s revenue for the quarter was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, sell-side analysts forecast that Biogen Inc. will post 15.83 earnings per share for the current year.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: BIIB091 MS trial reaches completion — Phase 2 readout setup provides a near-term pipeline catalyst that could materially affect investor sentiment if results are favorable. Biogen’s BIIB091 MS Trial Reaches Completion
• Positive Sentiment: New Board chair Maria C. Freire appointed — her experience in biomedical research, drug development and public–private partnerships could refocus partnerships and capital allocation, which investors may view as constructive for strategy and M&A/partnering optionality. New Biogen Chair Freire May Recast Partnerships And Capital Priorities
• Positive Sentiment: Analyst / media coverage highlights improved valuation and strong recent performance — articles noting Biogen as a value / turnaround candidate and highlighting recent gains can attract investors hunting discounted quality names. This supports momentum in the stock. Assessing Biogen (BIIB) Valuation
• Positive Sentiment: Broader ALS therapeutics market growth — a market-research report projects strong CAGR for ALS therapeutics, which is relevant because Biogen has neuro/ALS programs (supporting longer-term revenue upside if clinical progress continues). Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share
• Neutral Sentiment: Macro/guidance context and value-stock debate — a piece on “value stocks walking a fine line” highlights valuation risks vs. margin of safety; useful context but not BIIB-specific catalyst. 3 Value Stocks Walking a Fine Line
• Neutral Sentiment: Short-interest data appears noisy/invalid — reported short-interest entries show zero/NaN values and thus offer no reliable signal about positioning or squeeze risk. (Treat with caution.)
• Negative Sentiment: New Alzheimer’s startup Korsana raises $175M — fresh venture capital backing for an Alzheimer’s program (originating at Paragon) increases competition in the amyloid/Alzheimer’s R&D landscape; could pressure long-term franchise assumptions depending on Korsana’s program profile and trial outcomes. An Alzheimer’s startup emerges with $175M in venture backing

Institutional Investors Weigh In On Biogen

Institutional investors have recently added to or reduced their stakes in the stock. T. Rowe Price Investment Management Inc. lifted its position in shares of Biogen by 9.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,170,907 shares of the biotechnology company’s stock worth $206,068,000 after buying an additional 103,425 shares during the period. Compound Planning Inc. acquired a new position in Biogen during the fourth quarter worth $577,000. Axxcess Wealth Management LLC bought a new position in shares of Biogen during the fourth quarter valued at $401,000. Corient Private Wealth LLC boosted its stake in shares of Biogen by 32.9% in the 4th quarter. Corient Private Wealth LLC now owns 46,318 shares of the biotechnology company’s stock valued at $8,152,000 after purchasing an additional 11,456 shares in the last quarter. Finally, Strive Financial Group LLC bought a new stake in shares of Biogen in the 4th quarter worth about $35,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently commented on BIIB shares. HC Wainwright lifted their target price on shares of Biogen from $194.00 to $228.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Wall Street Zen downgraded shares of Biogen from a “buy” rating to a “hold” rating in a research note on Sunday, November 9th. Robert W. Baird cut their target price on shares of Biogen from $255.00 to $250.00 in a research note on Friday, October 31st. Wells Fargo & Company raised their price target on shares of Biogen from $190.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Sunday, February 8th. Finally, TD Cowen boosted their price objective on shares of Biogen from $175.00 to $215.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Twelve analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $205.04.

Insider Buying and Selling

In other Biogen news, insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the sale, the insider directly owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This represents a 24.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.18% of the stock is currently owned by company insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.